Ginger's Therapeutic Potential in Asthma

Prior treatment

• Cardiovascular conditions including myocardial infarction or stroke within the previous 3 months, uncontrolled hypertension, or known aortic aneurysm.
• Oral corticosteroid use within the previous 6 weeks.
• Use of an investigational treatment within the previous 30 days.
• Current drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.

Other illness

• Major chronic illness that, in the judgment of the study physician, would interfere with study participation, including non-skin cancer, uncontrolled diabetes mellitus, coronary artery disease, congestive heart failure, stroke, severe hypertension, renal failure, liver disorders, malabsorption disorders, immunodeficiency states, major neuropsychiatric disorders, or seizure disorders.
• History of physician-diagnosed chronic bronchitis, emphysema, or COPD.
• Cancer other than skin cancer.

Other

• Current use of ginger supplements.
• Use of anticoagulants, such as warfarin, rivaroxaban, or similar agents.
• Known adverse reaction to ginger or ginger products.
• Inability or unwillingness to provide written informed consent.

• Adults aged 18 years or older with mild to severe persistent asthma as defined by NIH National Asthma Education and Prevention Program (NAEPP) guidelines, with asthma that is not optimally controlled despite current use of inhaled corticosteroids with or without inhaled long-acting beta agonists.
• Treatment with inhaled corticosteroids (ICS), with or without long-acting beta-agonists/long-acting muscarinic antagonists and montelukast.
• Physician-diagnosed asthma confirmed by history/report, pulmonary function testing with FEV1 ≥60% predicted or ≥1.5 L, and methacholine testing with baseline methacholine PD20 \<16 mg/mL if taking ICS or \<8 mg/mL if not taking ICS at Visit 2.
• Non-smoker of tobacco, e-cigarettes, or marijuana for ≥1 year. Nicotine patch or gum is permitted.
• Smoking history of ≤10 pack-years.
• Suboptimal asthma control as determined by an Asthma Control Test (ACT) score ≤19 at the Screening and Randomization Visits.
• Ability to understand English or Spanish, understand the study procedures, and comply with them f r the entire study period.
• Participants of childbearing potential must have negative urine pregnancy testing as required by the protocol and agree to use effective contraception during the trial.